PDE1-IN-4

• UNSPSC Description:

  PDE1-IN-4 (compound 2g) is a potent and selective PDE1 (phosphodiesterase-1) inhibitor, with IC50 values of 10, 145, and 354 nM for PDE1C, PDE1A, and PDE1B, respectively. PDE1-IN-4 inhibits myofibroblast differentiation of human lung fibroblasts induced by TGF-β1. PDE1-IN-4 shows anti-fibrosis effects through the regulation of cAMP (3′,5′-cyclic adenosine monophosphate) and cGMP (3′,5′-cyclic guanosine monophosphate). PDE1-IN-4 can be used for idiopathic pulmonary fibrosis (IPF) research[1].

• Target Antigen:

  Calcium Channel; Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease;Neuronal Signaling

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/pde1-in-4.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC1=C(C(C2=CC3=C(C=C2)N(N=C3)C)C(C(O[C@@H](C4=CC=CC=C4)C)=O)=C(N1)C)C(O[C@@H](C5=CC=CC=C5)C)=O

• Molecular Weight:

  535.63

• References & Citations:

  [1]Huang MX, et al. Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects. J Med Chem. 2022 Jun 23;65(12):8444-8455.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  3031349-98-8